The role of COX-2 in intestinal cancer

C. S. Williams, R. L. Shattuck-Brandt, R. N. DuBois

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues whereas COX-2 is induced by a wide variety of stimuli and was initially identified as an immediate-early growth response gene. In addition, COX-2 expression is markedly increased in 85-90% of human colorectal adenocarcinomas while COX-1 levels remain unchanged. Several epidemiological studies have reported a 40-50% reduction in the risk of developing colorectal cancer in persons who chronically take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, which are classic inhibitors of COX. Genetic evidence also supports a role for COX-2, since mice null for COX-2 have an 86% reduction in tumour multiplicity in a background containing a mutated APC allele. These results strongly suggest that COX-2 contributes to the development of intestinal tumours and that inhibition of COX is chemopreventative. It is hoped that the chemopreventative effects of NSAIDs will be enhanced by the recent development of COX-2-specific inhibitors.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume8
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Intestinal Neoplasms
Cyclooxygenase 2
Cyclooxygenase 1
Prostaglandin-Endoperoxide Synthases
Anti-Inflammatory Agents
Cyclooxygenase Inhibitors
Cyclooxygenase 2 Inhibitors
Risk Reduction Behavior
Pharmaceutical Preparations
Aspirin
Genes
Prostaglandins
Epidemiologic Studies
Colorectal Neoplasms
Neoplasms
Adenocarcinoma
Alleles
Enzymes
Growth

Keywords

  • Chemopreventative
  • Colorectal carcinoma
  • Cyclooxygenase
  • Non-steroidal anti-inflammatory drugs
  • Prostaglandins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Williams, C. S., Shattuck-Brandt, R. L., & DuBois, R. N. (1999). The role of COX-2 in intestinal cancer. Expert Opinion on Investigational Drugs, 8(1), 1-12. https://doi.org/10.1517/13543784.8.1.1

The role of COX-2 in intestinal cancer. / Williams, C. S.; Shattuck-Brandt, R. L.; DuBois, R. N.

In: Expert Opinion on Investigational Drugs, Vol. 8, No. 1, 1999, p. 1-12.

Research output: Contribution to journalArticle

Williams, CS, Shattuck-Brandt, RL & DuBois, RN 1999, 'The role of COX-2 in intestinal cancer', Expert Opinion on Investigational Drugs, vol. 8, no. 1, pp. 1-12. https://doi.org/10.1517/13543784.8.1.1
Williams, C. S. ; Shattuck-Brandt, R. L. ; DuBois, R. N. / The role of COX-2 in intestinal cancer. In: Expert Opinion on Investigational Drugs. 1999 ; Vol. 8, No. 1. pp. 1-12.
@article{0b6b201900404c4fb2e134a089b6c4d8,
title = "The role of COX-2 in intestinal cancer",
abstract = "Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues whereas COX-2 is induced by a wide variety of stimuli and was initially identified as an immediate-early growth response gene. In addition, COX-2 expression is markedly increased in 85-90{\%} of human colorectal adenocarcinomas while COX-1 levels remain unchanged. Several epidemiological studies have reported a 40-50{\%} reduction in the risk of developing colorectal cancer in persons who chronically take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, which are classic inhibitors of COX. Genetic evidence also supports a role for COX-2, since mice null for COX-2 have an 86{\%} reduction in tumour multiplicity in a background containing a mutated APC allele. These results strongly suggest that COX-2 contributes to the development of intestinal tumours and that inhibition of COX is chemopreventative. It is hoped that the chemopreventative effects of NSAIDs will be enhanced by the recent development of COX-2-specific inhibitors.",
keywords = "Chemopreventative, Colorectal carcinoma, Cyclooxygenase, Non-steroidal anti-inflammatory drugs, Prostaglandins",
author = "Williams, {C. S.} and Shattuck-Brandt, {R. L.} and DuBois, {R. N.}",
year = "1999",
doi = "10.1517/13543784.8.1.1",
language = "English (US)",
volume = "8",
pages = "1--12",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The role of COX-2 in intestinal cancer

AU - Williams, C. S.

AU - Shattuck-Brandt, R. L.

AU - DuBois, R. N.

PY - 1999

Y1 - 1999

N2 - Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues whereas COX-2 is induced by a wide variety of stimuli and was initially identified as an immediate-early growth response gene. In addition, COX-2 expression is markedly increased in 85-90% of human colorectal adenocarcinomas while COX-1 levels remain unchanged. Several epidemiological studies have reported a 40-50% reduction in the risk of developing colorectal cancer in persons who chronically take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, which are classic inhibitors of COX. Genetic evidence also supports a role for COX-2, since mice null for COX-2 have an 86% reduction in tumour multiplicity in a background containing a mutated APC allele. These results strongly suggest that COX-2 contributes to the development of intestinal tumours and that inhibition of COX is chemopreventative. It is hoped that the chemopreventative effects of NSAIDs will be enhanced by the recent development of COX-2-specific inhibitors.

AB - Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues whereas COX-2 is induced by a wide variety of stimuli and was initially identified as an immediate-early growth response gene. In addition, COX-2 expression is markedly increased in 85-90% of human colorectal adenocarcinomas while COX-1 levels remain unchanged. Several epidemiological studies have reported a 40-50% reduction in the risk of developing colorectal cancer in persons who chronically take non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, which are classic inhibitors of COX. Genetic evidence also supports a role for COX-2, since mice null for COX-2 have an 86% reduction in tumour multiplicity in a background containing a mutated APC allele. These results strongly suggest that COX-2 contributes to the development of intestinal tumours and that inhibition of COX is chemopreventative. It is hoped that the chemopreventative effects of NSAIDs will be enhanced by the recent development of COX-2-specific inhibitors.

KW - Chemopreventative

KW - Colorectal carcinoma

KW - Cyclooxygenase

KW - Non-steroidal anti-inflammatory drugs

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0032945294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032945294&partnerID=8YFLogxK

U2 - 10.1517/13543784.8.1.1

DO - 10.1517/13543784.8.1.1

M3 - Article

VL - 8

SP - 1

EP - 12

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -